AtaiBeckley is being acquired by Eli Lilly at $6.75/share plus a $2.50 CVR—see the deal terms, milestone risks, and pipeline ...
Eli Lilly and Co LLY on Thursday agreed to acquire AtaiBeckley Inc. ATAI in a deal that values the clinical-stage mental ...
Canada's Drug Agency recognizes the clinical value of LEQEMBI®in slowing Alzheimer's progression and helping keep patients in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results